Read our Recent Headlines


Mar 07, 2014 by Dave Sobek

March 7 Biotech Update- Selling Feeding Selling

I am going to spend today talking about the sector in general and send this note out early in light of the significant sell off that started yesterday afternoon and.

Share 2 comments Read more
Mar 06, 2014 by Dave Sobek

March 6 Biotech Update- Oh the Humanity

It is Thursday again and as usual I do not have much time to write anything in depth. In general, the broad market looked good but the sector seemed pretty.

Mar 06, 2014 by Tony Pelz

Week’s Option Activity (2/20 ~ 3/04)

The following stocks had notable activity in their options during the past week(s): $CYTK (2/20): There were two large trades – one bullish and one bearish. (1) Bullish: 2,900 MAY.

Mar 05, 2014 by Dave Sobek

March 5 Biotech Update- Rumors Dispelled

I am back from vacation and it looks like I did not miss much (I say tongue in cheek). Of course, even though I missed two big days of trading,.

Mar 04, 2014 by Tony Pelz

Catalyst Watch – Vol. 2, Edition 6 (3/4/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Feb 28, 2014 by Dave Sobek

February 28 Biotech Update- Whose Afraid of a Little Selling?

Well, it was a good day for the market and sector, although it seems to be getting weaker as the day goes on. I think we need to be careful.

Feb 27, 2014 by Dave Sobek

February 27- A Quick Biotech Update

Thursday’s are always busy and today is no different. I wanted to post a quick update in terms of ECYT. 1. As I noted yesterday, I contacted the company and.

More From All Reports

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More